Joshua Haznedar

2.8k total citations
12 papers, 426 citations indexed

About

Joshua Haznedar is a scholar working on Molecular Biology, Infectious Diseases and Hepatology. According to data from OpenAlex, Joshua Haznedar has authored 12 papers receiving a total of 426 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 4 papers in Infectious Diseases and 4 papers in Hepatology. Recurrent topics in Joshua Haznedar's work include Hepatitis C virus research (4 papers), HIV/AIDS drug development and treatment (4 papers) and Angiogenesis and VEGF in Cancer (3 papers). Joshua Haznedar is often cited by papers focused on Hepatitis C virus research (4 papers), HIV/AIDS drug development and treatment (4 papers) and Angiogenesis and VEGF in Cancer (3 papers). Joshua Haznedar collaborates with scholars based in United States, Switzerland and United Kingdom. Joshua Haznedar's co-authors include Anuradha Rebbapragada, Igor B. Zhulin, Mark S. Johnson, Barry Taylor, Juthamas Sukbuntherng, Shem Patyna, Surinder Kaur, Stephen Schauer, Ashley M. Smith and Kristin R. Wildsmith and has published in prestigious journals such as Molecular Microbiology, Journal of Hepatology and Clinical Pharmacokinetics.

In The Last Decade

Joshua Haznedar

12 papers receiving 415 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joshua Haznedar United States	7	221	88	65	60	44	12	426
Francesco Sirci Italy	12	327 1.5×	65 0.7×	44 0.7×	83 1.4×	26 0.6×	17	511
Melanie R. Andrews Australia	7	376 1.7×	139 1.6×	44 0.7×	22 0.4×	25 0.6×	8	681
Robert D. Hoffman United States	12	335 1.5×	57 0.6×	77 1.2×	21 0.3×	36 0.8×	18	706
Ann‐Marie Simeone United States	11	208 0.9×	95 1.1×	49 0.8×	25 0.4×	69 1.6×	13	399
Anup D. Shah Australia	15	315 1.4×	30 0.3×	49 0.8×	30 0.5×	19 0.4×	29	535
John A. Wijsman Canada	13	160 0.7×	128 1.5×	48 0.7×	33 0.6×	40 0.9×	19	524
Mariangela Correa Brazil	10	336 1.5×	134 1.5×	47 0.7×	33 0.6×	28 0.6×	18	649
Michal Hofer Czechia	16	198 0.9×	50 0.6×	33 0.5×	96 1.6×	15 0.3×	40	539
Lisa J. Neilson United Kingdom	12	322 1.5×	109 1.2×	40 0.6×	47 0.8×	17 0.4×	21	595
Catherine Scott United Kingdom	10	239 1.1×	104 1.2×	203 3.1×	45 0.8×	16 0.4×	15	553

Countries citing papers authored by Joshua Haznedar

Since Specialization

Citations

This map shows the geographic impact of Joshua Haznedar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joshua Haznedar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joshua Haznedar more than expected).

Fields of papers citing papers by Joshua Haznedar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joshua Haznedar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joshua Haznedar. The network helps show where Joshua Haznedar may publish in the future.

Co-authorship network of co-authors of Joshua Haznedar

This figure shows the co-authorship network connecting the top 25 collaborators of Joshua Haznedar. A scholar is included among the top collaborators of Joshua Haznedar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joshua Haznedar. Joshua Haznedar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Wildsmith, Kristin R., Stephen Schauer, Ashley M. Smith, et al.. (2014). Identification of longitudinally dynamic biomarkers in Alzheimer’s disease cerebrospinal fluid by targeted proteomics. Molecular Neurodegeneration. 9(1). 22–22. 100 indexed citations

Washington, Carla, et al.. (2013). Single-dose Pharmacokinetics of the HCV Polymerase Inhibitor Mericitabine in Healthy Caucasian and Japanese Subjects. Drug Metabolism and Pharmacokinetics. 29(2). 141–147. 5 indexed citations

Haznedar, Joshua, et al.. (2013). Evaluation of the effect of mericitabine at projected therapeutic and supratherapeutic doses on cardiac repolarization in healthy subjects: A thorough QT/QTc study. Clinical Pharmacology in Drug Development. 3(3). 179–186. 2 indexed citations

Haznedar, Joshua, Thomas Marbury, Richard A. Robson, et al.. (2013). The Effect of Mild to Moderate Renal Impairment on the Pharmacokinetics of the Nucleoside Analog Hepatitis C Virus Polymerase Inhibitor Mericitabine. Drug Development Research. 75(2). 107–113. 1 indexed citations

Reddy, Micaela B., Yuan Chen, Joshua Haznedar, et al.. (2012). Impact of Low-Dose Ritonavir on Danoprevir Pharmacokinetics. Clinical Pharmacokinetics. 51(7). 457–465. 16 indexed citations

Haznedar, Joshua, Jennifer Fretland, Geraldine Leong, et al.. (2010). 753 IMPACT OF LOW DOSE RITONAVIR BOOSTING ON THE PHARMACOKINETICS OF RG7227 (ITMN-191), A HIGHLY POTENT AND SELECTIVE INHIBITOR OF THE HCV NS3/4A PROTEASE. Journal of Hepatology. 52. S293–S293. 6 indexed citations

Burger, Matthew T., Mark Knapp, Allan S. Wagman, et al.. (2010). Synthesis and in Vitro and in Vivo Evaluation of Phosphoinositide-3-kinase Inhibitors. ACS Medicinal Chemistry Letters. 2(1). 34–38. 23 indexed citations

Haznedar, Joshua, Shem Patyna, Carlo L. Bello, et al.. (2009). Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species. Cancer Chemotherapy and Pharmacology. 64(4). 691–706. 56 indexed citations

Patyna, Shem, et al.. (2009). Evaluation of the safety and pharmacokinetics of the multi‐targeted receptor tyrosine kinase inhibitor sunitinib during embryo–fetal development in rats and rabbits. Birth Defects Research Part B Developmental and Reproductive Toxicology. 86(3). 204–213. 37 indexed citations

10.

Patyna, Shem, Alexander Laird, Dirk B. Mendel, et al.. (2006). SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Molecular Cancer Therapeutics. 5(7). 1774–1782. 79 indexed citations

11.

Zhao, Yeping, Cheng Yong Yang, Joshua Haznedar, & Lida Antonian. (2001). Simultaneous determination of SU5416 and its phase I and phase II metabolites in rat and dog plasma by LC/MS/MS. Journal of Pharmaceutical and Biomedical Analysis. 25(5-6). 821–832. 6 indexed citations

12.

Rebbapragada, Anuradha, et al.. (2000). PAS domain residues involved in signal transduction by the Aer redox sensor of Escherichia coli. Molecular Microbiology. 36(4). 806–816. 95 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact